Humant erytrocytstroma somalloadsorptionsmedium: Insikter vidberedning och funktion

To ensure safe blood transfusions and to predict and manage haemolytic disease of the foetusand newborn, routine antibody screening is performed. When antibodies are detected inscreening, they must be identified to provide compatible blood for transfusion and to guideappropriate treatment or monitoring of pregnancy and foetus. Identification of alloantibodies inblood samples can be highly challenging, particularly when the sample contains autoantibodiesor multiple or broadly reacting alloantibodies. One technique that is occasionally required isalloadsorption, which is a complex and time-consuming method. To shorten the time andcomplexity of alloadsorption, a previous study by Wilson and Branch suggested that human redblood cell stroma could be used instead of fresh red blood cells for alloadsorption. In this study,we aimed to evaluate if small volumes of red blood cell stroma can be produced and whetherthe product is safe and functional for alloadsorption. Small volumes of human red blood cellstroma were produced from red blood cell units; The stroma was produced using digitonin andevaluated with patient samples containing known auto- and/or alloantibodies. The results showthat it is possible to produce small volumes of human red cell stroma, but the process is timeconsumingand yields limited quantities. Furthermore, some alloantibodies were shown to beadsorbed by stroma lacking the corresponding antigen, while other alloantibodies were notadsorbed at all despite the presence of the corresponding antigen on the stroma. This suggeststhat the functional performance of human red blood cell stroma as an alloadsorption mediumneeds to be optimized and validated in a larger study. In addition, the findings in this studyindicates that stroma production is best carried out by commercial manufacturers in largebatches.